GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Piotroski F-Score
中文

Surmodics (Surmodics) Piotroski F-Score

: 8 (As of Today)
View and export this data going back to 1998. Start your Free Trial

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Surmodics has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Surmodics's Piotroski F-Score or its related term are showing as below:

SRDX' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of Surmodics was 9. The lowest was 2. And the median was 6.


Surmodics Piotroski F-Score Historical Data

The historical data trend for Surmodics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 4.00 7.00 2.00 6.00

Surmodics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 3.00 5.00 6.00 8.00

Competitive Comparison

For the Medical Devices subindustry, Surmodics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics Piotroski F-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Surmodics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -7.733 + 7.346 + 6.694 + -0.786 = $5.5 Mil.
Cash Flow from Operations was -5.825 + 25.891 + 1.25 + -8.792 = $12.5 Mil.
Revenue was 27.198 + 52.483 + 27.97 + 30.552 = $138.2 Mil.
Gross Profit was 8.536 + 34.33 + 11.235 + 13.085 = $67.2 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(169.755 + 166.163 + 188.901 + 185.733 + 180.24) / 5 = $178.1584 Mil.
Total Assets at the begining of this year (Dec22) was $169.8 Mil.
Long-Term Debt & Capital Lease Obligation was $32.9 Mil.
Total Current Assets was $79.8 Mil.
Total Current Liabilities was $16.5 Mil.
Net Income was -4.083 + -5.651 + -14.728 + -7.843 = $-32.3 Mil.

Revenue was 26.106 + 24.854 + 25.988 + 24.933 = $101.9 Mil.
Gross Profit was 7.287 + 6.738 + 8.132 + 6.923 = $29.1 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(184.866 + 184.187 + 175.652 + 158.359 + 169.755) / 5 = $174.5638 Mil.
Total Assets at the begining of last year (Dec21) was $184.9 Mil.
Long-Term Debt & Capital Lease Obligation was $33.1 Mil.
Total Current Assets was $64.5 Mil.
Total Current Liabilities was $17.3 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Surmodics's current Net Income (TTM) was 5.5. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Surmodics's current Cash Flow from Operations (TTM) was 12.5. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=5.521/169.755
=0.03252334

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-32.305/184.866
=-0.1747482

Surmodics's return on assets of this year was 0.03252334. Surmodics's return on assets of last year was -0.1747482. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Surmodics's current Net Income (TTM) was 5.5. Surmodics's current Cash Flow from Operations (TTM) was 12.5. ==> 12.5 > 5.5 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=32.879/178.1584
=0.18454926

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=33.079/174.5638
=0.18949519

Surmodics's gearing of this year was 0.18454926. Surmodics's gearing of last year was 0.18949519. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=79.808/16.477
=4.84360017

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=64.462/17.264
=3.73389713

Surmodics's current ratio of this year was 4.84360017. Surmodics's current ratio of last year was 3.73389713. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Surmodics's number of shares in issue this year was 14.102. Surmodics's number of shares in issue last year was 13.983. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=67.186/138.203
=0.48613995

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=29.08/101.881
=0.28543104

Surmodics's gross margin of this year was 0.48613995. Surmodics's gross margin of last year was 0.28543104. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=138.203/169.755
=0.81413213

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=101.881/184.866
=0.55110729

Surmodics's asset turnover of this year was 0.81413213. Surmodics's asset turnover of last year was 0.55110729. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+0+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Surmodics has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Surmodics  (NAS:SRDX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Surmodics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Surmodics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics (Surmodics) Business Description

Traded in Other Exchanges
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
Executives
Jose H Bedoya director
David Dantzker other: See Explanation of Responses 80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr director
Gary R Maharaj director, officer: President & CEO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich officer: VP, Corp Dev & Strat Planning 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson officer: General Manager
John D. Manders officer: Corporate Controller 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber officer: Sr. VP of Legal, GC and Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana officer: VP, Clinical Affairs 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine director 1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides officer: Senior VP and CMO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton officer: VP of Research and Development 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight director 9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips officer: Dep. Gen. Counsel & Corp. Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens officer: General Manager - IVD 9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344

Surmodics (Surmodics) Headlines